Aptevo Therapeutics announced its expansion from its base in Seattle on September 4, 2025.
13 reports, 5 independent
Updated Sep 24
Gone quiet
- Reports
- 13
- Developments
- 2
- Repetition
- 85%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Aptevo Therapeutics announced its expansion from its base in Seattle on September 4, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Aptevo Therapeutics announced new agreements from its Seattle base.1 source
Aptevo Therapeutics announced expansion from Seattle.1 source
Keep exploring
The entities involved
-
Seattle
city in and county seat of King County, State of Washington, United States
-
Aptevo Therapeutics (United states)
company in Seattle, United States
Nothing else this week.
Coverage
Newest first; wire copies grouped- newjerseytelegraph.com
- californiatelegraph.com
- pr-inside.com
- hawaiitelegraph.comAptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone
- pr-inside.com
- ACCESS NewswireAptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules New candidates, APVO452 and APVO451, harness proprietary ADAPTIR-FLEXTM design to
- ACCESS NewswireAptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer Builds on the targeted immune activation model validated by mipletamig in AML, adapted for prostate cancer. Enginee
- ACCESS NewswireAptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update Mipletamig's 85% frontline AML remission rate and favorable safety profile drive APVO's differentiated CD3 portfolio